BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 36988316)

  • 21. Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway.
    Kuo HP; Chuang TC; Yeh MH; Hsu SC; Way TD; Chen PY; Wang SS; Chang YH; Kao MC; Liu JY
    J Agric Food Chem; 2011 Aug; 59(15):8216-24. PubMed ID: 21699261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SV40 T/t-common polypeptide inhibits angiogenesis and growth of HER2-overexpressing human ovarian cancer.
    Hsueh SP; Hsu WB; Wen CC; Wang WB
    Cancer Gene Ther; 2011 Dec; 18(12):859-70. PubMed ID: 21869825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
    Yin S; Mai Z; Liu C; Xu L; Xia C
    Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baicalein Inhibits Gastric Cancer Cell Proliferation and Migration through a FAK Interaction via AKT/mTOR Signaling.
    Qiao D; Jin J; Xing J; Zhang Y; Jia N; Ren X; Lin Z; Jin N; Chen L; Piao Y
    Am J Chin Med; 2021; 49(2):525-541. PubMed ID: 33641654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VPS33B interacts with NESG1 to suppress cell growth and cisplatin chemoresistance in ovarian cancer.
    Ning Y; Zeng Z; Deng Y; Feng W; Huang L; Liu H; Lin J; Zhang C; Fan Y; Liu L
    Cancer Sci; 2021 May; 112(5):1785-1797. PubMed ID: 33788346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-301a Promotes Cell Proliferation and Resistance to Apoptosis through PTEN/PI3K/Akt Signaling Pathway in Human Ovarian Cancer.
    Ni J; Chen Y; Fei B; Zhu Y; Du Y; Liu L; Guo L; Zhu W
    Gynecol Obstet Invest; 2021; 86(1-2):108-116. PubMed ID: 33596588
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lewis y antigen promotes the proliferation of ovarian carcinoma-derived RMG-I cells through the PI3K/Akt signaling pathway.
    Liu J; Lin B; Hao Y; Qi Y; Zhu L; Li F; Liu D; Cong J; Zhang S; Iwamori M
    J Exp Clin Cancer Res; 2009 Dec; 28(1):154. PubMed ID: 20003467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
    Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway.
    Zhong XS; Zheng JZ; Reed E; Jiang BH
    Biochem Biophys Res Commun; 2004 Nov; 324(2):471-80. PubMed ID: 15474452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells.
    Whitley BR; Beaulieu LM; Carter JC; Church FC
    Gynecol Oncol; 2007 Feb; 104(2):470-9. PubMed ID: 17070899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway.
    Zhang LQ; Yang HQ; Yang SQ; Wang Y; Chen XJ; Lu HS; Zhao LP
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819874773. PubMed ID: 31537175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Knockdown of JARID2 inhibits the proliferation and invasion of ovarian cancer through the PI3K/Akt signaling pathway.
    Cao J; Li H; Liu G; Han S; Xu P
    Mol Med Rep; 2017 Sep; 16(3):3600-3605. PubMed ID: 28765957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Upregulated microRNA-15b alleviates ovarian cancer through inhitbition of the PI3K/Akt pathway by targeting LPAR3.
    Li GC; Qin XL; Song HH; Li YN; Qiu YY; Cui SC; Wang YS; Wang H; Gong JL
    J Cell Physiol; 2019 Dec; 234(12):22331-22342. PubMed ID: 31140597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity.
    Yang H; Zhao R; Yang HY; Lee MH
    Oncogene; 2005 Mar; 24(11):1924-35. PubMed ID: 15688030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Repressing IRS1/2 by NT157 inhibits the malignant behaviors of ovarian cancer through inactivating PI3K/AKT/mTOR pathway and inducing autophagy.
    Li CX; Men CD; Yang WH; Chen R; Zhu JH; Cheng ZP
    Kaohsiung J Med Sci; 2023 Apr; 39(4):377-389. PubMed ID: 36727938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baicalein and Ly294002 induces liver cancer cells apoptosis via regulating phosphatidyl inositol 3-kinase/Akt signaling pathway.
    He K; Yu X; Wang X; Tang L; Cao Y; Xia J; Cheng J
    J Cancer Res Ther; 2018 Jun; 14(Supplement):S519-S525. PubMed ID: 29970718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-22 suppresses cell viability and EMT of ovarian cancer cells via NLRP3 and inhibits PI3K/AKT signaling pathway.
    Wu H; Liu J; Zhang Y; Li Q; Wang Q; Gu Z
    Clin Transl Oncol; 2021 Feb; 23(2):257-264. PubMed ID: 32524269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
    Basso AD; Solit DB; Munster PN; Rosen N
    Oncogene; 2002 Feb; 21(8):1159-66. PubMed ID: 11850835
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.